3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Magnetic Resonance-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids—Efficiency Assessment with the Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging and the Potential Role of the Administration of Uterotonic Drugs

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective: The assessment of the usefulness of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) when qualifying patients with uterine fibroids (UFs) for magnetic resonance-guided high-intensity ultrasound (MR-HIFU). Material and methods: This retrospective, single center study included 283 women who underwent DCE-MRI and were treated with MR-HIFU. The patients were divided according to non-perfused volume (NPV) as well as by the type of curve for patients with a washout curve in the DCE-MRI study and patients without a washout curve. The studied women were assessed in three groups according to the type of uterotonics administered. Group A (57 patients) received one dose of misoprostol/diclofenac transvaginally and group B (71 patients) received oxytocin intravenously prior to the MR-HIFU procedure. The remaining 155 women (group C) were treated with the traditional non-drug enhanced MR-HIFU procedure. Results: The average NPV value was higher in no washout group, and depended on the uterotonics used. Conclusions: We demonstrated a correlation between dynamic contrast enhancement curve types and the therapeutic efficacy of MR-HIFU. Our results suggest that DCE-MRI has the potential to assess treatment outcomes among patients with UFs, and patients with UFs that present with a washout curve may benefit from the use of uterotonic drugs. More studies are required to draw final conclusions.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Uterine fibroid management: from the present to the future

          Abstract Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Clinical presentations include abnormal bleeding, pelvic masses, pelvic pain, infertility, bulk symptoms and obstetric complications. Almost a third of women with leiomyomas will request treatment due to symptoms. Current management strategies mainly involve surgical interventions, but the choice of treatment is guided by patient's age and desire to preserve fertility or avoid ‘radical’ surgery such as hysterectomy. The management of uterine fibroids also depends on the number, size and location of the fibroids. Other surgical and non-surgical approaches include myomectomy by hysteroscopy, myomectomy by laparotomy or laparoscopy, uterine artery embolization and interventions performed under radiologic or ultrasound guidance to induce thermal ablation of the uterine fibroids. There are only a few randomized trials comparing various therapies for fibroids. Further investigations are required as there is a lack of concrete evidence of effectiveness and areas of uncertainty surrounding correct management according to symptoms. The economic impact of uterine fibroid management is significant and it is imperative that new treatments be developed to provide alternatives to surgical intervention. There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids due to the use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate (UPA). The efficacy of long-term intermittent use of UPA was recently demonstrated by randomized controlled studies. The need for alternatives to surgical intervention is very real, especially for women seeking to preserve their fertility. These options now exist, with SPRMs which are proven to treat fibroid symptoms effectively. Gynecologists now have new tools in their armamentarium, opening up novel strategies for the management of uterine fibroids.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Uterine fibroids

            Uterine fibroids (also known as leiomyomas or myomas) are common clonal neoplasms of the uterus. Fibroids have both smooth muscle and fibroblast components, in addition to a substantial amount of fibrous extracellular matrix, which all contribute to the pathogenetic process. Fibroids are extremely heterogeneous in their pathophysiology, size, location and clinical symptomatology. They are also a part of a range of disease in which some variants have facets of malignant behaviour but overall are benign. Risk for fibroids is associated with race; black women have a higher risk of developing fibroids earlier in life than their white counterparts and also develop more-severe forms of the disease. Clinically, fibroids account for one-third to half of all hysterectomies and are associated with substantial morbidity and health care costs for women of reproductive age. Indeed, current treatments are primarily surgical and interventional; approximately three-quarters of all fibroid treatments are hysterectomies. However, clinical innovations are emerging in the use of progesterone receptor modulators as a medical therapy. New information is rapidly accumulating about the genetic subgroups that lead to fibroid formation, which might aid further understanding of the clinical heterogeneity of this disease and lead to individualized treatments. This information is a crucial development given the current lack of high-quality evidence on which to base therapeutic decisions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Etiology, symptomatology, and diagnosis of uterine myomas.

              To review the currently available literature regarding the biology, etiology, symptoms, and diagnosis of uterine myomas. Literature review of 220 articles pertaining to uterine myomas. Although uterine myomas presently are not well understood, many advances have been made in the understanding of the hormonal factors, genetic factors, growth factors, and molecular biology of these benign tumors. Prospective, longitudinal studies are underway to characterize the risk factors for their development. When needed, the position of myomas can be best imaged by sonohysterography or magnetic resonance imaging. Evidence suggests that only submucous myomas appear to interfere with fertility, and only very rarely do myomas effect pregnancy outcome. A summary of the available literature regarding the biology, etiology, symptomatology, and diagnosis of myomas shows that, although they are still not well understood, much has been learned about uterine myomas.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Diagnostics (Basel)
                Diagnostics (Basel)
                diagnostics
                Diagnostics
                MDPI
                2075-4418
                16 April 2021
                April 2021
                : 11
                : 4
                : 715
                Affiliations
                [1 ]Department of Obstetrics and Gynecology, Pro-Familia Hospital, 35-302 Rzeszow, Poland
                [2 ]Second Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, 01-809 Warsaw, Poland
                [3 ]Department of Radiology and Nuclear Medicine, Institute of Medical Sciences, Faculty of Medicine, University of Rzeszow, 35-310 Rzeszow, Poland; ela.luczynska@ 123456op.pl (E.Ł.); filipowskajustyna@ 123456me.com (J.F.)
                [4 ]Department of Radiology, Pro-Familia Hospital, 35-302 Rzeszow, Poland
                [5 ]Department of Gynecological Oncology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland; arturczekierdowski@ 123456umlub.pl
                Author notes
                [* ]Correspondence: tomasz.lozinski@ 123456pro-familia.pl (T.Ł.); michal.ciebiera@ 123456cmkp.edu.pl (M.C.); Tel.: +48-662-106-226 (T.Ł.); +48-22-5690-274 (M.C.)
                Author information
                https://orcid.org/0000-0001-5780-5983
                https://orcid.org/0000-0003-4872-7172
                Article
                diagnostics-11-00715
                10.3390/diagnostics11040715
                8072686
                b9572915-693a-4b41-8663-36eac9b5c05e
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 09 March 2021
                : 13 April 2021
                Categories
                Article

                uterine fibroid,leiomyoma,magnetic resonance-guided high-intensity focused ultrasound (mr-hifu),diffusion-weighted magnetic resonance imaging (dwi),dynamic contrast-enhanced magnetic resonance imaging (dce-mri)

                Comments

                Comment on this article